

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.co

Biodeal Pharmaceuticals raises Rs 385 Cr growth investment from RMB Capitalworks

10 August 2026 | News

Investment validates Biodeal's leadership in specialty pharmaceutical manufacturing



Biodeal Pharmaceuticals, one of India's leading specialty pharmaceutical Contract Development and Manufacturing Organisations (CDMOs), has announced a growth investment of Rs 385 crore from RMB Capitalworks, a joint venture between Rand Merchant Bank and Capitalworks Group.

The investment marks a significant milestone in Biodeal's growth journey and will support the company's next phase of expansion across specialty pharmaceuticals, manufacturing capabilities, and regulated markets.

The investment will support Biodeal's next phase of expansion, strengthening its positions across Asian markets while accelerating growth across CIS, LATAM, Africa and Europe.

"This investment represents much more than capital - it is a strong endorsement of the platform we have built over the past two decades. At Biodeal, we have consistently focused on creating differentiated capabilities in specialty pharmaceuticals, anchored by leadership in nasal drug delivery and a relentless focus on quality and manufacturing excellence. This milestone reflects the strength of what we've built and the scale of what lies ahead," said Anurag Kumar, CMD, Biodeal Pharmaceuticals.

"We work closely with founders to co-create solutions that unlock personal value and provide the long-term financial stability needed to execute ambitious growth plans. Healthcare is a core focus for us, and Biodeal fits our thesis of a differentiated player primed for rapid growth," said Anshuman Malur, Managing Partner, RMB Capitalworks.

Biodeal has delivered consistent profitable growth over the past five years, with FY26 revenue estimated to grow 60%+ year-on-year and EBITDA margins expanding further. The company is entering its next phase of growth with a clear ambition; to strengthen its position as a globally trusted specialty pharmaceutical partner while advancing confidently on its path towards a planned public listing.